Navigation Links
Pharmacyclics Reports Third Quarter 2008 Financial Results

- Company to Host Conference Call at 4:30 p.m. EDT Today -

SUNNYVALE, Calif., April 24 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2008. The net loss for the third quarter of fiscal 2008 was $7.0 million, or $0.27 per share, compared to a net loss of $6.8 million, or $0.26 per share, in the third quarter of fiscal 2007.

Total operating expenses were $7.2 million in the third quarter of fiscal 2008 compared to $7.4 million for the third quarter of fiscal 2007, a decrease of $0.2 million. Share-based compensation expense was $0.5 million in the third quarter of fiscal 2008 compared to $0.9 in the third quarter of fiscal 2007. The decrease in total operating expenses in the third quarter of fiscal 2008 was primarily related to reduced personnel expenses due to lower headcount and lower share-based compensation expense, partially offset by increased outside pre-clinical and drug manufacturing expenses associated with the Company's HDAC, Btk and Factor VIIa inhibitor programs.

Pharmacyclics also reported its financial results for the nine months ended March 31, 2008. The net loss for the nine months ended March 31, 2008 was $19.7 million, or $0.76 per share, compared to a net loss of $19.2 million, or $0.82 per share, for the nine months ended March 31, 2007.

As of March 31, 2008 the company's cash, cash equivalents and marketable securities totaled $21.3 million compared to $38.8 million at June 30, 2007. The company expects cash used in operations over the next four quarters to be approximately $16 million.

"In the remainder of 2008, we anticipate expanding our clinical programs with our oral HDAC inhibitor, PCI-24781, by initiating a Phase 1/2 trial evaluating it in hematologic malignancies, and filing investigational new drug applications for our Factor VIIa inhibitor and our Btk inhibitor," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "We own worldwide rights to these novel compounds, which have the potential to address unmet needs in large patient populations."

Recent Events and Upcoming Milestones

-- Data was published in the February 7 issue of Leukemia characterizing

the company's novel highly-selective histone deacetylase (HDAC)

inhibitor showing that the drug candidate, PCI-34501, inhibits HDAC-8

with 200-1000 fold selectivity over other HDAC enzymes.

-- Six presentations relating to the company's HDAC, Factor VIIa and Btk

programs were made at the American Association for Cancer Research

(AACR) 2008 Annual Meeting held in April 2008:

- Reseachers from the University of Texas M.D. Anderson Cancer

Center conducted laboratory studies with the company's HDAC

inhibitor, PCI-24781, demonstrating inhibition of NFkB, a

transcription factor known to drive tumor growth;

- Other researchers at M.D. Anderson found that treatment of animals

with resistant tumors that overexpress the protein ErbB2, or

Her2, with PCI-24781 led to control of tumors in 80 percent of the

animals, with most achieving partial response;

- The company's Factor VIIa inhibitor, PCI-27483, led to inhibition

of tumor growth in animal models of human pancreatic tumors; and

- PCI-32765, the company's orally available, selective inhibitor of

Bruton's tyrosine kinase, or Btk, was shown to block B-cell

receptor mediated signaling in vitro in the treatment of B-cell

lymphomas. Treatment with PCI-32765 in lymphoma-bearing animal

models resulted in inhibition of tumor growth and significant

activity in animal models of arthritis.

-- Plan to initiate Phase 1/2 trial evaluating HDAC inhibitor, PCI-24781,

given orally in hematologic malignancies in second quarter of 2008.

-- Plan to file investigational new drug (IND) application for the

company's Factor VIIa inhibitor in the second half of 2008.

-- Plan to file IND application for the company's small molecule Btk

inhibitor in the second half of 2008.

Conference Call and Webcast Details

The Company will hold a conference call today at 4:30 p.m. EDT to discuss third quarter 2008 financial results and achievements. To participate in the conference call, please dial 800-497-0451 for domestic callers and 706-758-3306 for international callers and reference conference passcode, 43624853. To access the live audio broadcast or the subsequent archived recording, log on to The archived version of the webcast will be available on the company's website for one month.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about our expected cash used in operations over the next four quarters, the initiation of and enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to accurately predict our future cash needs; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Pharmacyclics, Inc.

(a development stage enterprise)

Condensed Statements of Operations

(unaudited) (in thousands, except per share data)

Three Months Nine Months

Ended March 31, Ended March 31,

2008 2007 2008 2007

Grant revenue $ -- $ -- $ -- $19

Operating expenses:

Research and development 5,120 5,669 14,822 15,557

General and administrative 2,100 1,705 5,923 5,315

Total operating expenses 7,220 7,374 20,745 20,872

Loss from operations (7,220) (7,374) (20,745) (20,853)

Interest and other, net 240 615 1,075 1,626

Net loss $(6,980) $(6,759) $(19,670) $(19,227)

Basic and diluted net loss per share $(0.27) $(0.26) $(0.76) $(0.82)

Shares used to compute basic and

diluted net loss per share 25,994 25,938 25,983 23,581

Condensed Balance Sheets

(unaudited, in thousands)

March 31, June 30,

2008 2007


Cash, cash equivalents and marketable securities $21,272 $38,762

Other current assets 611 961

Total current assets 21,883 39,723

Property and equipment, net 633 849

Other noncurrent assets 523 523

$23,039 $41,095

Liabilities and stockholders' equity

Current liabilities $2,348 $2,615

Long-term obligations 74 79

Stockholder's equity 20,617 38,401

$23,039 $41,095

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
2. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
3. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
(Date:4/30/2017)... San Francisco, CA (PRWEB) , ... April 30, 2017 , ... ... Bay Area, is proud to announce an updated blog post on the continual issue ... are "too busy" to seek a second opinion before dental surgery, but this can ...
(Date:4/29/2017)... ... April 29, 2017 , ... Natural Family Planning ... observe the naturally occurring signs and symptoms of a woman's menstrual cycle. ... , Natural family planning and fertility are special interests of Dr. Bazger’s. She ...
(Date:4/29/2017)... UTAH (PRWEB) , ... April 29, 2017 , ... Phytomer ... region. As a Phytomer Account Manager, Smith’s role is to provide excellent ... brands that make up The Phytomer Group. Smith comes to Phytomer with a wealth ...
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... More than ... so what are Americans doing in their leisure time that causes hearing loss? May ... habits that may be contributing to hearing loss, as well as schedule a hearing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: